Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123689508> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2123689508 abstract "Cellular immunotherapy is a highly effective treatment option for patients with acute myeloid leukaemia (AML) as shown by the low relapse rate after allogeneic stem cell transplantation. However, many patients are not eligible for this treatment. This has lead to the development of various immunotherapeutic approaches that aim at inducing autologous cellular and humoral immune responses against AML and specifically against residual leukaemic stem cells (LSCs).Dendritic cells (DCs) are important regulators of the human immune response. We have developed a three-day DC manufacturing protocol that starts with peripheral blood monocytes, e.g. from AML patients in remission following intensive chemotherapy. By using a cytokine cocktail containing a synthetic TLR7/8 agonist, the resulting DCs develop improved immunogenicity. For healthy donors as well as for AML patients, we were able to show that these DCs display a positive costimulatory profile, secrete high levels of IL-12p70, show chemotaxis to CCR7 ligands, and activate NK cells. After loading the DCs with mRNA, they effectively induce antigen-specific T cell responses with a strong type-1 polarization. Due to these properties, this DC type seems highly suitable for application in cancer immunotherapy.We have recently initiated a phase I/II clinical trial for the application of these DCs in the setting of AML postremission strategy. WT1 and PRAME were chosen as leukaemia-associated antigens due to their overexpression on leukaemic blasts and specifically on cells that are enriched for LSCs. DCs transfected with mRNA encoding CMV-pp65 are included into the vaccine as an adjuvant as well as a surrogate antigen. 20 patients with a non-favourable risk profile or with confirmed minimal residual disease (MRD), but who are not eligible for allogeneic stem cell transplantation, will be included. The primary objective of this study is to evaluate feasibility and safety of this immunotherapeutic approach. Important secondary endpoints are immune responses to the applied antigens and MRD control. First results of this study will be presented." @default.
- W2123689508 created "2016-06-24" @default.
- W2123689508 creator A5003069482 @default.
- W2123689508 creator A5033935778 @default.
- W2123689508 creator A5038058895 @default.
- W2123689508 creator A5058606136 @default.
- W2123689508 creator A5063176873 @default.
- W2123689508 creator A5067305238 @default.
- W2123689508 creator A5072372922 @default.
- W2123689508 creator A5080108562 @default.
- W2123689508 creator A5089599067 @default.
- W2123689508 date "2014-03-01" @default.
- W2123689508 modified "2023-09-22" @default.
- W2123689508 title "P55. Dendritic cell vaccination for postremission therapy in AML" @default.
- W2123689508 doi "https://doi.org/10.1186/2051-1426-2-s2-p29" @default.
- W2123689508 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4072282" @default.
- W2123689508 hasPublicationYear "2014" @default.
- W2123689508 type Work @default.
- W2123689508 sameAs 2123689508 @default.
- W2123689508 citedByCount "0" @default.
- W2123689508 crossrefType "journal-article" @default.
- W2123689508 hasAuthorship W2123689508A5003069482 @default.
- W2123689508 hasAuthorship W2123689508A5033935778 @default.
- W2123689508 hasAuthorship W2123689508A5038058895 @default.
- W2123689508 hasAuthorship W2123689508A5058606136 @default.
- W2123689508 hasAuthorship W2123689508A5063176873 @default.
- W2123689508 hasAuthorship W2123689508A5067305238 @default.
- W2123689508 hasAuthorship W2123689508A5072372922 @default.
- W2123689508 hasAuthorship W2123689508A5080108562 @default.
- W2123689508 hasAuthorship W2123689508A5089599067 @default.
- W2123689508 hasBestOaLocation W21236895081 @default.
- W2123689508 hasConcept C147483822 @default.
- W2123689508 hasConcept C203014093 @default.
- W2123689508 hasConcept C2776090121 @default.
- W2123689508 hasConcept C2777701055 @default.
- W2123689508 hasConcept C2777863537 @default.
- W2123689508 hasConcept C2778170410 @default.
- W2123689508 hasConcept C2780868878 @default.
- W2123689508 hasConcept C502942594 @default.
- W2123689508 hasConcept C71924100 @default.
- W2123689508 hasConcept C8891405 @default.
- W2123689508 hasConceptScore W2123689508C147483822 @default.
- W2123689508 hasConceptScore W2123689508C203014093 @default.
- W2123689508 hasConceptScore W2123689508C2776090121 @default.
- W2123689508 hasConceptScore W2123689508C2777701055 @default.
- W2123689508 hasConceptScore W2123689508C2777863537 @default.
- W2123689508 hasConceptScore W2123689508C2778170410 @default.
- W2123689508 hasConceptScore W2123689508C2780868878 @default.
- W2123689508 hasConceptScore W2123689508C502942594 @default.
- W2123689508 hasConceptScore W2123689508C71924100 @default.
- W2123689508 hasConceptScore W2123689508C8891405 @default.
- W2123689508 hasLocation W21236895081 @default.
- W2123689508 hasLocation W21236895082 @default.
- W2123689508 hasOpenAccess W2123689508 @default.
- W2123689508 hasPrimaryLocation W21236895081 @default.
- W2123689508 hasRelatedWork W1485212944 @default.
- W2123689508 hasRelatedWork W1531105746 @default.
- W2123689508 hasRelatedWork W1966030601 @default.
- W2123689508 hasRelatedWork W1973295077 @default.
- W2123689508 hasRelatedWork W1991657770 @default.
- W2123689508 hasRelatedWork W2009348430 @default.
- W2123689508 hasRelatedWork W2035831579 @default.
- W2123689508 hasRelatedWork W2087665046 @default.
- W2123689508 hasRelatedWork W2133686399 @default.
- W2123689508 hasRelatedWork W2162578269 @default.
- W2123689508 hasRelatedWork W2252299908 @default.
- W2123689508 hasRelatedWork W2735429607 @default.
- W2123689508 hasRelatedWork W2787663719 @default.
- W2123689508 hasRelatedWork W2902244218 @default.
- W2123689508 hasRelatedWork W2908868862 @default.
- W2123689508 hasRelatedWork W2964351348 @default.
- W2123689508 hasRelatedWork W2988170355 @default.
- W2123689508 hasRelatedWork W3028759332 @default.
- W2123689508 hasRelatedWork W3129062629 @default.
- W2123689508 hasRelatedWork W3163829944 @default.
- W2123689508 isParatext "false" @default.
- W2123689508 isRetracted "false" @default.
- W2123689508 magId "2123689508" @default.
- W2123689508 workType "article" @default.